Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

154 results about "Immunologic Tolerance" patented technology

The failure of the immune system to respond to an antigen that previously caused an immune response.

Marker for detecting immune escape of lung cancer cells and application thereof

The invention discloses a marker for detecting immune escape of lung cancer cells and application of the marker. The marker is subjected to APOC2-K70 site milk acylation modification. The specific APOC2-K70 site lactoacylation antibody is prepared, and lactoacylation modification of the APOC2-K70 site in an immunotherapy lung cancer sample can be specifically detected, so that whether lung cancer cells tolerate immunotherapy or not can be predicted. According to the invention, APOC2-K70 lactoacylation modification is taken as a lung cancer immune tolerance detection index, and the lactoacylation antibody at the APOC2-K70 site is combined with immunotherapy, so that lung cancer cells can be effectively killed, and a new strategy is provided for precise treatment of lung cancer.
Owner:SHANGHAI SONGJIANG DISTRICT CENTRAL HOSPITAL +1

Rapamycin lipid polymer hybrid nanoparticles

The present application relates to a nanoparticle comprising a lipid, a polymer and an immunosuppressive agent, wherein the lipid comprises an anionic lipid and / or a PEGylated lipid. Furthermore, the invention also relates to a preparation method of the nanoparticles, a pharmaceutical composition containing the nanoparticles, and application of the nanoparticles and / or the pharmaceutical composition in inducing immune tolerance.
Owner:SHANGHAI VITALGEN BIOPHARMA CO LTD

In-vitro preparation method and application of natural follicular regulatory T cells

The invention relates to the technical field of immunology, and discloses an in-vitro preparation method and application of a natural follicular regulatory T cell. The method comprises the following steps: firstly, sorting wild mouse spleen cells by using magnetic beads to obtain initial CD4 + T lymphocytes, then carrying out induced differentiation by using an antibody and a specific cytokine, and carrying out continuous stimulation and culture by adopting two different cytokine polarization conditions, thereby obtaining the natural follicular regulatory T cells. The invention provides the method for preparing the natural follicular regulatory T cells in vitro, the natural follicular regulatory T cells with enough quantity are expected to be obtained, and an important tool and a treatment means are provided for research on immune tolerance related diseases such as autoimmune diseases and organ transplantation.
Owner:HOSPITAL OF DERMATOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES

Screening method and application of human-mouse protein high homologous target antibody based on fully humanized antibody mouse

The invention belongs to the field of antibody development, and discloses a screening method and application of a human-mouse protein high homologous target antibody based on a fully humanized antibody mouse. Aiming at the problem of weak antibody response caused by immune tolerance of human-mouse high homologous targets (protein homology is greater than or equal to 95%), the following scheme is provided: in embryonic stem cells (ES cells) of HUGO-Mabfully humanized antibody transgenic mice, a mouse target gene (such as ACVR2A) is knocked out through a Turbo Knockout technology, and homozygous knockout ES clones are screened; carrying out microinjection on the clones to the whitened B6 mouse blastocyst, and transplanting a pregnant mouse to obtain a Founder mouse; the Founder mouse is subjected to target antigen immunization for more than or equal to 4 times (the Freund's complete adjuvant is used for the first time), and the titer of the serum antibody is detected. According to the invention, 100% homozygous knockout chimeric efficiency is realized in the Founder stage, the mouse construction period is shortened from traditional 8-10 months to 3-4 months, and the diversity and affinity of the antibody are significantly improved (titer reaches 1: 729,000). The obtained antibody can be used for preparing medicines for treating tumors or autoimmune diseases.
Owner:CYAGEN BIOSCIENCES (SUZHOU) INC

Multifunctional antibody-ligand traps to counteract immune tolerance

The invention provides multifunctional antibody-ligand traps and methods of using them to counteract immune tolerance and / or immune dysfunction. The multifunctional antibody-ligand traps and fusion proteins of the invention can counteract immune dysfunction in order to restore and unleash antitumor or pathogen-directed immune responses. Provided here are promising immunotherapeutic agents for treatment and prevention of cancers, infectious diseases, and immuno-inflammatory disorders.
Owner:JOHNS HOPKINS UNIVERSITY

Hypoallergenic Craa a4 enzymatic hydrolysate with immune tolerance inducing potential and preparation method of hypoallergenic Craa a4 enzymatic hydrolysate

The invention provides a hypoallergenic Cra a 4 enzymatic hydrolysate with immune tolerance inducing potential and a preparation method thereof, the method comprises the following steps: obtaining a Cra a 4 amino acid sequence from NCBI, predicting T cell epitopes and B cell epitopes of the Cra a 4 amino acid sequence by using bioinformatics software, and totally obtaining five predicted T cell epitopes and five predicted B cell epitopes; predicting a restriction enzyme cutting site on the Craa4 by using a PeptideCutter and BIOPEP-UWM protease restriction enzyme cutting site prediction website, comparing the predicted T cell epitope and the predicted B cell epitope, and screening out trypsin as protease for enzymolysis of the Craa4 protein; the method comprises the following steps: optimizing enzymolysis conditions of trypsin, and carrying out enzymolysis on a allergen Cra a 4 protein under the optimized enzymolysis conditions, so as to obtain a low-sensitization Cra a 4 enzymolysis product with the potential of inducing immune tolerance. The low-sensitization Cra a 4 enzymolysis product prepared by the method can be applied to prevention of oyster allergic diseases, side effects in immunotherapy are reduced, and the treatment safety is improved.
Owner:XIAMEN OCEAN VOCATIONAL & TECH COLLEGE

Cell bionic nanoparticles as well as construction method and application thereof

ActiveCN119139348AReduce immune response levelsGreat clinical valueSenses disorderPowder deliveryInflammatory factorsAutoimmune condition
The invention belongs to the technical field of cell bionic nano-drugs, and particularly discloses a cell bionic nano-particle as well as a construction method and application thereof. And performing simple ultrasonic fusion on the target cell membrane and the hydrophobic nano-core to obtain the cell bionic nano-particles. The bionic nano-cell can effectively inherit and simulate functional protein on the surface of a source cell membrane, systematically replace functions of the source cell in physiological and pathological processes, such as inflammatory factor adsorption, migration factor adsorption and the like, interfere and inhibit the disease process from the cellular mechanism, regulate and control cell composition and immune microenvironment of a focus part, and improve the immune function of the source cell membrane. The medicine does not need to be additionally carried. Aiming at the related pathogenesis of immune tolerance deficiency, the invention innovatively provides a therapeutic strategy for constructing immune tolerance. The homology and inherent immunosuppressive ability of tumor cells to the focus part of the autoimmune disease are reversely used, immune tolerance of the focus part based on immune checkpoints is reconstructed, meanwhile, target cells are replaced to adsorb autoimmune antibodies, and the immune response level is reduced.
Owner:KUNMING MEDICAL UNIVERSITY

Engineered cells for inducing tolerance

To provide compositions, methods and uses for inducing immunosuppression and tolerance as defined by suppression of an immune response to an antigen.SOLUTION: Provided is cells that are engineered so as to increase the cellular level of cellular FLICE [Fas-associated death domain (FADD)-like IL-1β-converting enzyme]-inhibitory protein (CFLAR). The engineered cells have an ability to induce tolerance. Enhanced tolerogenicity is useful for prolonging survival of a foreign transplant and for treatment of autoimmune diseases.SELECTED DRAWING: None
Owner:BIONTECH SE +1

In-vitro preparation method and application of induced follicular regulatory T cells

The invention belongs to the technical field of immunology, and particularly discloses an in-vitro preparation method and application of an induced follicular regulatory T cell iTfr.The in-vitro preparation method comprises the steps that mouse spleen single-cell suspension or healthy human peripheral blood is obtained, peripheral blood mononuclear cells are obtained, then initial CD4 + T cells are obtained through immunomagnetic bead sorting, and iTfr cells are obtained; then carrying out induced differentiation by using an antibody and a specific cytokine, and carrying out continuous stimulation and culture by adopting two different cytokine polarization conditions, so as to obtain the iTfr cell. The invention provides a method for preparing the iTfr cells in vitro, which is expected to obtain an enough number of induced follicular regulatory T cells, and provides an important tool and a treatment means for in vitro research of immune tolerance related diseases such as autoimmune diseases and organ transplantation.
Owner:HOSPITAL OF DERMATOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES

Application of selenium-containing preparation in medicine for antagonizing NK cell injury caused by chemotherapy and medicine

The invention provides an application of a selenium-containing preparation in a drug for antagonizing NK cell injury caused by chemotherapy and a drug for antagonizing cisplatin or adriamycin induced NK cell injury. At present, common cancer treatment methods include operative treatment, chemotherapy, radiotherapy and immunotherapy, and chemotherapy is still a main treatment means for most advanced malignant tumors. Meanwhile, chemotherapy has an inhibition effect on an immune system, which is mainly manifested in that the immune system of a patient is damaged and T cells and NK cells are reduced due to direct killing of chemotherapy drugs on immune cells, so that the normal physiological function of the immune system is influenced, tumor cells can be induced to generate immune tolerance, and the metastasis of the tumor cells is accelerated. The selenium-containing preparation is applied to antagonism of induced damage of cis-platinum or adriamycin to NK cells, damage of cis-platinum or adriamycin to NK cells can be antagonized, and effectiveness of chemotherapy and immunotherapy is improved.
Owner:JINAN UNIVERSITY

Immune tolerance inducer for sublingual administration

To provide an immune tolerance inducer for sublingual administration applicable to sublingual immunotherapy.SOLUTION: An immune tolerance inducer for sublingual administration comprises a phosphorylcholine compound (P), represented by the formula (1) below (where, each symbol is as defined in the specifications), as well as an allergen.SELECTED DRAWING: None
Owner:NATIONAL UNIVERSITY CORPORATION OITA UNIVERSITY +1

Construction method and anti-tumor application of multifunctional adoptive T cell

The invention discloses a construction method and anti-tumor application of a multifunctional adoptive T cell. An active targeting peptide is fused on the surface of the multifunctional adoptive T cell through a membrane fusion liposome, and the membrane fusion liposome comprises an inner core and a shell; the inner core comprises iron oxide, a nano material and mRNA; the shell comprises phospholipid structure lipid, cationic functional lipid and active targeting peptide modified polyethylene glycol functional lipid. The multifunctional T cell provided by the invention has enhanced tumor infiltration capability, capability of overcoming immune tolerance of tumor cells and capability of reversing an immunosuppressive tumor microenvironment, and the preparation process is simple to operate, time-saving and efficient.
Owner:SUN YAT SEN UNIV +1

Immune cell binding polypeptides

The present disclosure provides immune cell binding polypeptides (ICBP) comprising a binding moiety capable of binding to ILT2 and / or ILT4 polypeptides, at least one immunosuppressive polypeptide, and a backbone polypeptide. The ICBP is suitable for inducing immune tolerance. The present disclosure provides methods of inducing immune tolerance.
Owner:CUE BIOPHARMA INC

Transplant tolerance induction with carbodiimide treated tolerizing vaccine

PendingEP4417212A3Organic active ingredientsMetabolism disorderTolerance inductionRegimen
The present disclosure is related to compositions and systems for inducing immune tolerance for transplanted cells, organ, or tissues in a transplant recipient. Also provided herein are methods of making and methods of administering tolerizing vaccines / regimen or preparatory regimens.
Owner:REGENTS OF THE UNIVERSITY OF MINNESOTA

A CD4 helper t cell epitope fusion peptide and vaccine thereof

The present application provides a CD4 helper T cell epitope fusion peptide, its encoding nucleic acid and an immune composition comprising the same. The epitope fusion peptide comprises a cytomegalovirus epitope. The epitope fusion peptide provided by the present application can greatly improve the cellular immune response level of the target immunogen, especially a weak immunogen, and is an effective means to overcome the immune system's immune tolerance to antigens, especially tumor antigens or infection-related antigens, and is suitable for efficiently enhancing the efficacy of vaccines.
Owner:VACDIAGN BIOTECH

PH and ultrasound double-response type oncolytic microorganism as well as preparation method and application thereof

The invention belongs to the technical field of biological medicines, and particularly discloses a pH and ultrasound double-response type oncolytic microorganism as well as a preparation method and application thereof. On the basis of a tumor targeting platform, a mild thermal response gene loop expression GM-CSF and a surface-coated oncolytic microbial system are integrated, chemotherapeutic drugs are released in a tumor core area, and immunogenic cell death is induced. A thermal response loop is accurately activated through low-intensity focused ultrasound, and engineering bacteria are promoted to express GM-CSF and secrete a large amount of mannose modified OMVs. Due to the nanometer size and mannose targeting of the OMVs, the OMVs are efficiently enriched in lymph nodes, the OMVs are reprogrammed into an immune activation state from an immune tolerance state, and the OMVs and ICD cooperate to promote dendritic cell maturation, tumor antigen presentation and activation of tumor killer T cells, so that a remarkable and powerful treatment effect is achieved in various tumor models, and the application prospect is wide. A new strategy is provided for remodeling the lymph node immune microenvironment and enhancing the anti-tumor immune response.
Owner:PEOPLES HOSPITAL OF HENAN PROV

Methods and Compositions for Inducing CAS Immunotolerance to Support CRISPR-CAS In Vivo Gene Editing

Disclosed are tolerogenic compositions useful for inducing a tolerogenic immune response against a CRISPR-Cas effector polypeptide in a subject. The tolerogenic composition can comprise a) one or more microparticles, b) one or more regulatory T cell (Treg) stimulants encapsulated within each microparticle, and c) a CRISPR-Cas effector polypeptide or an immunogenic fragment thereof, or a fusion polypeptide comprising a CRISPR-Cas effector polypeptide or an immunogenic fragment thereof. The tolerogenic composition can comprise a) a soluble microneedle array, b) one or more agents that promote the differentiation of tolerogenic DCs in the soluble microneedle array, and c) a CRISPR-Cas effector polypeptide or an immunogenic fragment thereof, or a fusion polypeptide comprising a CRISPR-Cas effector polypeptide or an immunogenic fragment thereof.
Owner:UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION +1

Methods of inducing immune tolerance to clotting factors

The present disclosure provides methods inducing immune tolerance in a human, comprising administering to the human an effective amount of a composition or a chimeric protein comprising a clotting factor and an Fc region.
Owner:BIOVERATIV THERAPEUTICS INC +1

Methods of evading immune rejection

The present disclosure is directed to methods, compositions and devices capable of avoiding foreign body responses to implanted material. This technology utilizes polymer encapsulated engineered cells that produce natural, cell-generated cytokines to elicit a tailored immune response to implanted materials for applications in diabetes, immune tolerance, and organ transplantation.
Owner:WILLIAM MARCH RICE UNIVERSITY

Cellular populations and uses thereof

Disclosed are methods of identifying immunosuppressive TR1 regulatory T cells, including methods of diagnosing the presence of immune tolerance, methods of producing immunosuppressive regulatory T cells, and methods of eliciting immune tolerance in a subject. These methods include screeing T cells to detect Eomes +IL-10+ T cells or expressing recombinant Eomes in T cell populations to generate immunosuppressive regulatory T cells.
Owner:COUNCIL OF THE QUEENSLAND INST OF MEDICAL RES

HBV vaccine inducing pres-specific neutralizing antibodies

A Hepatitis B virus (HBV) vaccine comprising a fusion protein of a preS polypeptide fused to at least one grass pollen allergen peptide, for use in the treatment of a subject to induce HBV neutralizing antibodies, wherein the subject is an immune tolerant human subject and said treatment comprises repeated vaccination to break immune tolerance against HBV.
Owner:VIRAVAXX AG

Peptide Conjugated Particles

The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
Owner:NORTHWESTERN UNIV

Double-antigen type 1 diabetes mellitus vaccine targeting intestinal M cells and preparation method of double-antigen type 1 diabetes mellitus vaccine

The invention relates to a double-antigen type 1 diabetes vaccine targeting intestinal M cells and a preparation method of the double-antigen type 1 diabetes vaccine, and belongs to the technical field of biology. The method comprises the following steps: connecting human GAD65191-320, INS17-110 and CKS9 targeting peptide CKSTHPLSC through G4S connecting peptide according to the sequence, optimizing lactobacillus codon preference, inserting the human GAD65191-320, the INS17-110 and the CKS9 targeting peptide CKSTHPLSC into a pNZ8148 vector together, transforming constructed recombinant plasmids into MC1061 competent escherichia coli for cloning amplification, and extracting the recombinant plasmids; the recombinant plasmid is electrically transferred into NZ9000 competent lactococcus lactis to construct a GAD65191-320 + INS17-110 + CKSTHPLSC recombinant lactic acid bacteria vaccine, and after amplification, Nisin is used for inducible expression of the fusion protein. According to the present invention, the recombinant lactic acid bacteria vaccine is orally taken to immunize STZ induced BALB / c diabetes model mice, such that the mice can be induced to produce the GAD65 + INS specific antibody, and the proliferation of regulatory T cells and dendritic cells secreting interleukin 10 can be promoted so as to induce the immune tolerance, inhibit the differentiation of young DCs and maintain the blood glucose level, such that the type 1 diabetes mellitus can be prevented and treated.
Owner:INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI

Composition for inducing immune tolerance

The present invention provides a composition for inducing immune tolerance, the composition containing: pluripotent stem cells that have the ability to form teratoma cells; or teratoma cells derived from the pluripotent stem cells. The present invention also provides a method for inducing immune tolerance in a mammalian individual, the method including administering an effective amount of the pluripotent stem cells or the teratoma cells to a mammal individual for which immune tolerance is desired. By inducing immune tolerance in a mammalian individual by an immune-tolerance-inducing composition and an immune tolerance inducer, autoimmune diseases can be treated and allogeneic transplantation can be performed under a condition in which a reduced amount of an immunosuppressant is used compared to the amount conventionally used, or under a condition in which no immunosuppressant is used.
Owner:HOKKAIDO UNIVERSITY +1

Composition for immune tolerance induction and use in gene therapy

Provided are compositions and methods for reducing pre-existing antibodies against viral vector or gene-editing related proteins. The compositions showed reduction in various antibody titers by administration of a liposome composition complexed with a protein or fragment thereof of a viral vector. The liposomes comprise phosphatidylcholine and phosphatidylserine, wherein some or all of the PS is present as lyso-PS. The compositions and methods can be used in conjunction with gene therapy and nucleic acid based vector based vaccinations and therapeutics.
Owner:THE RES FOUNDATION FOR THE STATE UNIV OF NEW YORK

Methods for breaking immunological tolerance using multiple guide rnas

To provide compositions and improved methods for producing antigen-binding proteins (e.g., antibodies) that bind an epitope on a foreign target antigen of interest (e.g., a human target antigen of interest) that shares the epitope with a self-antigen or is homologous to the self-antigen.SOLUTION: Methods according to the present invention comprise reducing tolerance of the foreign antigen in non-human animals such as rodents (e.g., mice or rats) (optionally comprising in their germline humanized immunoglobulin heavy and / or light chain loci) by employing two or more guide RNAs (gRNAs) to create paired double-strand breaks at different sites within a single target genomic locus.SELECTED DRAWING: Figure 3
Owner:REGENERON PHARMACEUTICALS INC

Engineered Plant Virus-Based Nanoparticles and Intravenous Formulations Thereof for Autoimmune Therapy

The present invention provides intravenous pharmaceutical compositions comprising engineered plant virus-based nanoparticles for the treatment or prevention of autoimmune conditions. The nanoparticles display immunodominant peptides that induce immune tolerance in a subject when administered intravenously. The invention further provides methods of manufacturing virus-based nanoparticles, including production in plant expression systems and optional viral inactivation, to render them suitable for therapeutic use in mammals. Also provided are methods of intravenous administration of the pharmaceutical compositions to a subject in need thereof for treating or preventing autoimmune conditions.
Owner:DIAMANTE SOCIETA BENEFIT SRL

Use of cd52 protein in the preparation of a medicament for the treatment of recurrent miscarriage

The application discloses application of CD52 protein in preparation of a medicine for treating recurrent spontaneous abortion, and belongs to the technical field of biological medicine. It is found that the CD52 protein can target and inhibit abnormal activation of effector T cells at a maternal-fetal interface, reduce release of proinflammatory factors (such as IFN-gamma), thereby reversing immune tolerance imbalance and improving pregnancy outcome. The CD52 protein is applied to the treatment of recurrent spontaneous abortion for the first time, and has the advantages of high targeting and high safety.
Owner:ZHONGNAN HOSPITAL OF WUHAN UNIV